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Abstract
Background: As a component of the progression from genomic to proteomic analysis, there is a
need for accurate assessment of protein post-translational modifications such as phosphorylation.
Traditional kinase assays rely heavily on the incorporation of γ-P32  radiolabeled isotopes,
monoclonal anti-phospho-protein antibodies, or gel shift analysis of substrate proteins. In addition
to the expensive and time consuming nature of these methods, the use of radio-ligands imposes
restrictions based on the half-life of the radionucleotides and pose potential health risks to
researchers. With the shortcomings of traditional assays in mind, the aim of this study was to
develop a high throughput, non-radioactive kinase assay for screening Glycogen Synthase Kinase-
3beta (GSK-3β) activity.
Results: Synthetic peptide substrates designed with a GSK-3β phosphorylation site were assayed
with both recombinant enzyme and GSK-3β immunoprecipitated from NIH 3T3 fibroblasts. A
molecular weight shift equal to that of a single phosphate group (80 Da.) was detected by surface
enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF-MS) in a GSK-
3β target peptide (2B-Sp). Not only was there a dose-dependent response in molecular weight shift
to the amount of recombinant GSK-3β used in this assay, this shift was also inhibited by lithium
chloride (LiCl), in a dose-dependent manner.
Conclusion: We present here a novel method to sensitively measure peptide phosphorylation by
GSK-3β that, due to the incorporation of substrate controls, is applicable to either purified enzyme
or cell extracts. Future studies using this method have the potential to elucidate the activity of GSK-
3β in vivo, and to screen enzyme activity in relation to a variety of GSK-3β related disorders.
Background
Phosphorylation is believed to be the most common pro-
tein post-translational covalent modification and is
known to occur in the processing of as many as 1/3 of
eukaryotic gene products [1]. That the mammalian
genome is predicted to encode as many as 1000 different
protein phosphatases and twice as many kinases under-
lines the importance of protein phosphorylation in cellu-
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lar function [2,3]. One of the most diverse protein kinases
studied to-date is the constitutively active serine/threo-
nine kinase, Glycogen Synthase Kinase-3beta (GSK-3β).
Originally identified for its role in the regulation of glyco-
gen metabolism [4], it is now known that GSK-3β plays a
key role in cellular processes as diverse as cytoskeletal reg-
ulation [5], cell cycle progression [6,7], apoptosis [8], cell
fate and specification [9], and transcriptional/transla-
tional initiation [10,11]. Therefore, functional kinase
activity of GSK-3β is important in a variety of biological
and biochemical processes and altered GSK-3β activity
can contribute to a number of pathological processes
including bipolar mood disorder [12-14], schizophrenia
[15], heart disease [16,17], neurodegeneration [18] Alzhe-
imer's disease [11,19] and diabetes mellitus [11,19,20].
Elucidating the direct activity of GSK-3β phosphorylation
activity in vivo is therefore important in contributing to
understanding the molecular basis of a variety of disease
states.
Traditionally, kinase assays are performed using radioac-
tive isotopes and scintillation counting for determination
of γ-P32 incorporation into a substrate [21]. These meth-
ods are relatively insensitive, as they are unsuitable for
screening discrete changes in enzyme activity, and are lim-
ited by radiation-induced peptide degradation and the
short half-life of γ-P32. Furthermore, exposure to radioac-
tive isotopes poses a health risk, and thus movement
towards a non-radioactive kinase assay is preferable. Exist-
ing non-radioactive kinase assays utilize band shifts on
non-denaturing polyacrylamide gels and the use of mon-
oclonal antibodies that are indirectly quantified or visual-
ized using Western Blot analysis or immunofluorescence.
Such methods are limited by the requirements of specific
antibodies for well-characterized phosphorylated residues
on a protein of interest, numerous incubation steps, and
their time consuming nature when multiple substrates are
being screened at once.
This study focuses on the development of a novel, rapid,
non-radioactive method of screening GSK-3β activity
using surface enhanced laser desorption/ionization time
of flight mass spectrometry (SELDI-TOF-MS). This kinase
assay utilizes peptide substrates that have been designed
with a well-known GSK-3β phosphorylation site based on
the translation initiation factor eIF2B [22,23]. GSK-3β has
an unusual preference for target proteins that have under-
gone a previous phospho-priming event, and the enzyme
generally recognizes substrates with a Ser-Xaa-Xaa-Xaa-
Ser(P) motif [22,24]. The synthetic substrate peptides
were prepared with a serine residue at a position equiva-
lent to the GSK-3β phosphorylation site on eIF2B (n), and
either an alanine (2B-A), serine (2B-S) or phosphoserine
(2B-Sp) at the n+4 position. The phospho-primed serine
containing peptide, 2B-Sp is subject to phosphorylation
by GSK-3β, while the serine and alanine containing pep-
tides, 2B-S and 2B-A, remain unphosphorylated due to
the lack of the phosphoserine residue requisite for GSK-3β
phosphorylation. To broaden the applicability of this
assay to cell extracts potentially containing priming
kinases such as casein kinase-1, the 2B-S peptide has been
incorporated as a control substrate that can be converted
to 2B-Sp, and subsequently phosphorylated by GSK-3β.
The dual use of SELDI-TOF-MS and GSK-3β target pep-
tides allows for the detection of changes in their molecu-
lar weight, or m/z ratio, when subjected to the kinase
activity of GSK-3β. Essentially, the target peptides are
added in a kinase assay with GSK-3β (either recombinant,
or immunoprecipitated) and submitted for mass spectro-
metric analysis. The peptide samples are spotted on gold
(Au) chips, covered with energy absorbing matrix (EAM),
inserted into a PBS II ProteinChip® Reader, and desorbed/
ionized with a nitrogen-based laser. The components of
the sample are then resolved based on time of flight from
the chip surface to the detector, which is proportional to
their mass to charge ratio (m/z) [25]. Through the selec-
tive use of peptide substrates with predetermined mass
signatures, SELDI-TOF-MS can identify when a specific
peptide substrate has been phosphorylated via a mass/
charge (m/z) shift of 80 Da., the molecular weight equiv-
alent of a single phosphate group.
Although matrix assisted mass spectrometric techniques
are not particularly quantitative in nature [26], the ability
to detect and readily resolve discrete changes in molecular
weight makes up for this downfall. Surface enhanced tech-
nologies utilizing chromatographic or preactivated sur-
face chips can allow for quantitative measurement.
SELDI-TOF-MS was used in this study to determine the
phosphorylation status of GSK-3β target peptides through
detection of changes in peptide m/z ratio. GSK-3β kinase
activity can be derived from this information, an observa-
tion of enzyme activity that can only be inferred from less
direct assays such as the phosphorylation state of the
enzyme itself.
By capitalizing on the ease, sensitivity and reproducibility
of SELDI-TOF-MS, a novel non-radioactive, mass spec-
trometry-based method has been developed to study
phosphorylation events. This method can be used to elu-
cidate the signaling activity of a specific kinase in vivo, and
is limited only by the specificity of the kinase for its sub-
strate peptides [27]. This kinase detection method is
highly specific, and accurate protein profiles can be gener-
ated from minimal sample volumes in a short amount of
time. SELDI-TOF-MS is a relatively new proteomic tool
that has been used in the discovery of disease-related
biomarkers in carcinomas such as pancreatic ductal aden-
ocarcinoma [28,29], malignant prostate cancer [30],BMC Biochemistry 2005, 6:29 http://www.biomedcentral.com/1471-2091/6/29
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breast cancer [31], and ovarian neoplasms [32]. Under the
premise of this type of GSK-3β activity detection, it is also
possible to deduce the kinase activity of GSK-3β in more
complex cellular signaling systems.
Results
SELDI-TOF-MS analysis of GSK-3β target substrates
Parent m/z ratio peaks of GSK-3β target synthetic pep-
tides, 2B-Sp, 2B-S, and 2B-A were determined by prepar-
ing samples containing untreated peptide substrates for
SELDI-TOF-MS analysis. Native molecular weights were
obtained and calibrated in accordance with manufacturer
m/z ratio read-outs of each of 2B-Sp, 2B-S, and 2B-A pep-
tides. The m/z ratio of 2B-Sp, 2B-S, and 2B-A peptides
were 2063.2 Da., 1983.2 Da., and 1967.2 Da., respectively
(Figure 1A).
Recombinant GSK-3β induces a shift in the m/z peak of 2B-
Sp
Mass to charge ratios of peptide substrates 2B-Sp, 2B-S,
and 2B-A incubated with recombinant GSK-3β were ana-
lyzed using SELDI-TOF-MS. A shift of peptide m/z ratio of
2063.2 Da. to 2143.2 Da. was detected in 2B-Sp kinase
assay samples only, corresponding to the addition of a
single phosphate group of 80 Da. (Figure 1B upper). The
m/z ratio for 2B-S and 2B-A peptides remained at their
parent molecular weight of 1983.2 Da. and 1967.2 Da.,
respectively (Figure 1B).
The m/z ratio shift of 2B-Sp is GSK-3β dose-dependent
A dose-response assay determined that the 80 Da. increase
in m/z ratio of the 2B-Sp peptide corresponded to amount
of recombinant GSK-3β used in each assay (Figure 2A).
SELDI-TOF-MS analysis of GSK-3β target peptides Figure 1
SELDI-TOF-MS analysis of GSK-3β target peptides. (A) GSK-3β target peptide substrates and representative SELDI-
TOF-MS analysis spectra. SELDI-TOF-MS representative spectra of peptides 2B-Sp, 2B-S, and 2B-A reveal a single m/z peak 
corresponding to their natural molecular weights (2063.2 Da., 1983.2 Da., and 1967.2 Da., respectively). (B) SELDI-TOF-MS 
spectra of target peptides subjected to a kinase assay with recombinant GSK-3β. Each target peptide substrate was incubated 
with 6.25 ng of recombinant GSK-3β enzyme, a magnesium/ATP kinase reaction mixture, and incubated for 20 minutes at 
37°C. GSK-3β kinase activity was detected as an 80 Da. shift in peptide m/z ratio.BMC Biochemistry 2005, 6:29 http://www.biomedcentral.com/1471-2091/6/29
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Kinase assays were performed with 125 ng of the 2B-Sp
peptide and increasing amounts of recombinant GSK-3β
(0 – 6.25 ng). Percent 2B-Sp phosphorylation increased
from 0% at 0 ng of GSK-3β to almost 80% when 6.25 ng
of recombinant GSK-3β was used in the assay (Figure 2B).
2B-Sp peptide m/z shift is sensitive to GSK-3β inhibition by 
lithium chloride
Kinase assays were performed with LiCl, an established
GSK-3β inhibitor, and NaCl, a salt with no known inhib-
itory action on GSK-3β activity. Kinase assays were pre-
pared with 2B-Sp peptide, recombinant GSK-3β, and
increasing concentrations (0 – 50 mM) of LiCl or NaCl
(Figure 3). As the concentration of LiCl increased, there
was a corresponding decrease in the 2143.2 Da. 2B-Sp
peak, and a marked increase in the signal intensity of the
parent 2B-Sp 2063.2 Da. peptide peak (Figure 3). Percent
phosphorylation ratios decreased from 100% at 0 mM
LiCl to 6.64% at 50 mM LiCl (Figure 3). In contrast, NaCl
had no effect on the kinase activity of GSK-3β, as an 80
Da. shift in 2B-Sp m/z ratio was evident regardless of the
concentration of NaCl used in the assay (Figure 3).
Radiolabeled kinase assays confirm recombinant GSK-3β 
phosphorylation of 2B-Sp target peptide
A traditional kinase assay was performed to detect recom-
binant GSK-3β-mediated incorporation of radiolabeled
[γ-P32] ATP into the peptide substrates described previ-
ously. Once background radioactivity readings derived
from reactions without recombinant GSK-3β were nor-
malized, minimal radioactivity readings were detected in
assays containing the 2B-S and 2B-A target peptides
(620.78 +/- 206.92 cpm and 192.95 +/- 64.31 cpm,
respectively) relative to γ-P32 incorporation into 2B-Sp
(6701.66 +/- 873.56 cpm) (Figure 4). Very low levels of
substrate phosphorylation were also observed in the pres-
ence of LiCl (510.61 +/- 66.06 cpm). A one-way analysis
of variance (ANOVA) was conducted for radioactivity
incorporation into GSK-3β target peptides. Following the
significant ANOVA [F(3,8) = 16.16, p < 0.01, power =
0.858], Tukey post-hoc tests (p < 0.05) showed that the
2B-Sp target peptide group had significantly more radio-
activity incorporation than the other groups tested. * Indi-
cates a significant mean difference in radioactivity
incorporation.
A dose-dependent shift in 2B-Sp m/z ratio in response to increasing amounts of recombinant GSK-3β Figure 2
A dose-dependent shift in 2B-Sp m/z ratio in response to increasing amounts of recombinant GSK-3β. 125 ng of 
2B-Sp was added to kinase assays with increasing amounts of recombinant GSK-3β (0 – 6.25 ng). (A) Raw data is presented 
here as a SELDI-TOF-MS m/z read-out. (B) Enzyme activity was measured as percent 2B-Sp phosphorylation, and was deter-
mined through the ratio calculation of the 2143.2 Da. peak intensity to the total signal intensity values of all peptide present in 
the sample (2063.2 Da. and 2143.2 Da. peaks combined). Pooled data are plotted as mean values +/- SEM (n = 3) at each data 
point.BMC Biochemistry 2005, 6:29 http://www.biomedcentral.com/1471-2091/6/29
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Determination of GSK-3β activity in NIH 3T3 cell lysates
GSK-3β activity was determined from immunoprecipi-
tated NIH 3T3 cell lysates as described above for recom-
binant GSK-3β. As shown in figure 5,
immunoprecipitated NIH 3T3 cell lysates displayed two
peaks at 2063.2 Da. and 2143.2 Da. (Figure 5). The 2B-S
and 2B-A peptides remained at original molecular weights
of 1983.2 Da. and 1967.2 Da. in all samples tested.
Discussion
Although genomic research has made remarkable discov-
eries in the last few decades, there are still many unsolved
mysteries regarding the actual protein products of the
genetic code. As it is estimated that approximately 50% of
all proteins undergo one or more post-translational mod-
ifications that alter both their structure and function, it is
clear that meaningful predictions of protein status cannot
be made by genomic research alone [33]. Protein phos-
phorylation is a post-translational modification that is
essential for many cellular pathways, and for this reason
has become the focus of recent proteomic-based research.
Phosphoproteomics has stepped into a light of its own
with many advances being made in mass spectrometric
techniques which allow for rapid, high-throughput pro-
tein detection and resolution [34]. With such advances in
proteomic analysis, it is now possible to explore intracel-
lular phosphorylation events and the role they play in
complex cellular signaling systems.
GSK-3β generally has two sites of substrate recognition
which can be divided into two different classes: substrates
which require a phospho-priming event, and those which
do not [35]. Previous studies have determined that syn-
thetic peptides designed with a phospho-primed serine
four residues downstream of a serine residue are the most
effective substrates for assaying GSK-3β activity in vitro
[22,35].
The eIF2B sequence-like peptide 2B-Sp and recombinant
GSK-3β were used to optimize the conditions needed for
the assay, including sample preparation, and SELDI-TOF-
MS analysis. It was determined that 6.25 ng of recom-
binant GSK-3β resulted in a 80 Da. shift in molecular
weight for 100% of the target serine residue in the 2B-Sp
peptide and that a stepwise reduction in recombinant
GSK-3β to 2.5 ng resulted in a dose-response reaction with
respect to phosphorylation status of the peptide (Figure
2). Furthermore, assays with 6.25 ng of recombinant GSK-
3β and control peptides 2B-S and 2B-A did not produce an
80 Da. shift in m/z ratio (Figure 1B). These results indicate
that recombinant GSK-3β kinase activity was unable to
phosphorylate the 2B-A control peptide and that, in the
absence of priming kinases, the SB-S peptide was also an
effective control for specific GSK-3β phosphorylation
(Figure 1B).
To further support our findings that the 80 Da. shift in m/
z ratio of the 2B-Sp peptide was due to the addition of a
phosphate moiety and the result of GSK-3β activity, inhib-
itory assays were performed. An established inhibitor of
GSK-3β, lithium chloride (LiCl), and a non inhibitor con-
trol salt, sodium chloride (NaCl) were added to subse-
quent assays. Increasing concentrations of LiCl inhibited
the 80 Da. shift in molecular weight in a dose-dependent
manner (Figure 3). In contrast, NaCl was shown to be
ineffective in altering the m/z ratio of the target serine on
the 2B-Sp peptide (Figure 3), confirming LiCl specific
inhibition of GSK-3β kinase activity.
Although an 80 Da. shift in molecular weight of the 2B-Sp
peptide is consistent with a phosphorylation event cata-
lyzed by GSK-3β, traditional γ-P32 assays were performed
to confirm the incorporation of a phosphate group into
the target peptide. Scintillation counting confirmed the
incorporation of γ-P32 into the 2B-Sp peptide but not the
2B-S and 2B-A controls (Figure 4). Similarly, the addition
of LiCl inhibited GSK-3β kinase activity on the 2B-Sp pep-
tide (Figure 4).
2B-Sp m/z ratio shifts in response to varying amounts of lith- ium chloride, and sodium chloride Figure 3
2B-Sp m/z ratio shifts in response to varying amounts 
of lithium chloride, and sodium chloride. GSK-3β spe-
cificity for the 2B-Sp target peptide was examined in a kinase 
assay with lithium chloride (LiCl, green bars, n = 3) a well-
known inhibitor of GSK-3β, and sodium chloride (NaCl, pur-
ple bars, n = 3), a salt with no known GSK-3β inhibitory 
characteristics. Increasing amounts of LiCl (0–50 mM), or 
NaCl (0–50 mM) were added to kinase assays containing 125 
ng of 2B-Sp peptide, and 6.25 ng of recombinant GSK-3β. M/
z ratios were subsequently analyzed using SELDI-TOF-MS. 
Pooled data for LiCl assays are represented as mean +/- SEM 
values. NaCl assays are represented as mean values.BMC Biochemistry 2005, 6:29 http://www.biomedcentral.com/1471-2091/6/29
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Having validated our method of screening GSK-3β activity
by showing specificity for the target peptide used and that
this method is capable of detecting changes in enzyme
activity, we further validated this system for use in a bio-
logical model. Serum-starved NIH 3T3 fibroblasts were
lysed and GSK-3β was immunoprecipitated. Enzyme
activity was assessed in the same manner as described pre-
viously for recombinant purified GSK-3β. As shown in fig-
ure 5, immunoprecipitated cell lysates from fibroblasts
display a large 2063.2 Da. peak and a smaller but clearly
detectable peak at 2143.2 Da. corresponding to non-
phosphorylated and phosphorylated 2B-Sp peptide
respectively. Relative quantitation of areas under the
peaks from three replicate experiments indicated that
23.0% +/- 3.5% of the 2B-Sp peptide had been phospho-
rylated. This demonstrates that this assay system is appli-
cable to biological systems where the sensitive detection
of changes in GSK-3β activity is required. In contrast, the
2B-S peptide control remained at its original molecular
weight of 1983.2 Da. indicating that there was no detect-
able contamination from priming kinases in the immuno-
precipitated lysates. The 2B-A peptide remained at
original molecular weight of 1967.2 Da. in all samples
indicating that there were no other, less specific kinases
contaminating the immunoprecipitates and that both 2B-
A and 2B-S peptides are effective controls for this assay.
Conclusion
The kinase activity detection method developed in this
study has applications outside of its use for screening
GSK-3β activity. The versatility of this method lies in the
simplicity of its design: employing the use of mass spec-
trometry to detect small changes of molecular weight in
peptide substrates specific for a protein kinase of interest.
If target peptide substrates can be synthesized with a
sequence specific for the protein kinase (or phosphatase)
of interest, this method is applicable to virtually any sign-
aling pathway in which kinase activity and phosphoryla-
tion play a role.
This report describes in general terms the components
required and sensitivity of this SELDI-TOF assay for
GSK3β activity. It is emphasized that cell-type specific
optimization is required to utilize this assay system.
Immunoprecipitation of cell lysates is a necessary and
essential component of this assay as it facilitates the meas-
urement of GSK3β activity specifically and, ideally, in the
absence of interfering factors such as priming kinases.
Optimal conditions for immunoprecipitation are neces-
sary to achieve target specificity as well as reproducible
and sensitive detection of changes in GSK3β activity.
The demonstration of altered GSK-3β kinase activity in a
variety of pathologies related to fibroproliferative disease
lead to its selection for this study. Not only is GSK-3β
activity implicated in a variety of developmental, cell sig-
naling, and regulatory mechanisms [36], dysfunctional
GSK-3β activity is now being explored in Alzheimer's dis-
ease [37], non-insulin dependent diabetes mellitus
(NIDDM) [38], and in our laboratory, Dupuytren's con-
tracture, a fibroproliferative disease whose molecular
pathology is not presently understood. With the develop-
ment of this SELDI-TOF-MS based assay for screening
GSK-3β kinase activity, future studies can be directed at
elucidating the role of this protein kinase in a variety of
disease states in hopes of characterizing their molecular
pathways.
Methods
Synthetic peptide substrates
Peptides used in this study (AnaSpec Incorporated, San
Jose, CA) were;
Traditional kinase assay: γ-32P incorporation into target and  control peptides Figure 4
Traditional kinase assay: γ-32P incorporation into tar-
get and control peptides. Kinase assays were prepared 
with target peptides 2B-Sp, 2B-S, 2B-A, and γ-32P labeled 
ATP. Incorporation of γ-32P into each peptide was quantified 
in counts per minute (cpm) by liquid scintillation counting. 
Assays were performed with 6.25 ng of recombinant GSK-
3β, and in the absence or presence of 50 mM LiCl. An assay 
devoid of GSK-3β enzyme in the presence of 2B-Sp control-
led for background radioactivity readings. Incorporation of 
radioactivity in cpm units were plotted as means +/- SEM (n 
= 9). * denotes statistical significance by ANOVA and Tukey's 
post-hoc analysis (p < 0.05).BMC Biochemistry 2005, 6:29 http://www.biomedcentral.com/1471-2091/6/29
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• Biotin-Arg-Arg-Ala-Ala-Glu-Glu-Leu-Asp-Ser-Arg-Ala-
Gly-SerPO4-Pro-Gln-Leu-OH (2B-Sp, molecular weight
2063.2 Da.)
• Biotin-Arg-Arg-Ala-Ala-Glu-Glu-LeulAsp-Ser-Arg-Ala-
Gly-Ser-Pro-Gln-Leu-OH
(2B-S, molecular weight 1983.2 Da.)
• Biotin-Arg-Arg-Ala-Ala-Glu-Glu-Leu-Asp-Ser-Arg-Ala-
Gly-Ala-Pro-Gln-Leu-OH
(2B-A, molecular weight 1967.2 Da.)
Peptide substrates were diluted with HPLC grade water to
working dilutions and stored at -80°C for later use in sub-
sequent kinase assays.
Cell culture
NIH 3T3 cells were cultured in Dulbecco's Modified
Eagle's Medium (DMEM) with 10% Bovine calf serum
and fresh 2 mM glutamine (Invitrogen Canada Inc. Burl-
ington, Ontario). Cells were cultured in 6 well trays and,
when 80% confluent, were serum starved in DMEM for 12
hours.
Protein extraction and immunoprecipitation
Whole-cell lysates were isolated using RIPA buffer with
protease inhibitors (Sigma-Aldrich, Milwaukee, WI) and
total protein concentrations were determined by BCA
(Pierce Biotechnology, Rockford, IL). GSK-3β was immu-
noprecipitated using anti- GSK-3β (BD Biosciences, Mis-
sissauga, ON) using standard protocols. In brief, 50–200
µg of cell lysate was cleared with 20 µl of Protein A/G Plus
agarose beads (Santa Cruz Biotechnology, Santa Cruz,
CA), on a rotator at 4°C for 1 hr. The suspension was cen-
trifuged briefly, the supernatant was separated and 2 µg of
GSK-3β antibody was added and rotated at 4°C for 1 hr.
20 µL of Protein A/G Plus Agarose beads were added and
the suspension was rotated at 4°C overnight. The suspen-
sion was centrifuged briefly and the supernatant dis-
carded. The bead/antibody/GSK-3β complex was washed
3 times with 40 µl of magnesium/ATP cocktail at 4°C
immediately prior to the kinase reaction.
Kinase assays
The activity of recombinant GSK-3β (Upstate, Lake Placid
NY) or immunoprecipitated GSK-3β derived from NIH
3T3 fibroblasts was measured in a kinase assay with 125
ng of peptide (2B-Sp, 2B-S or 2B-A) and 6.25 ng of either
recombinant or immunoprecipitated GSK-3β. The kinase
reaction mixture consisted of 5 µl of 5 × Reaction Buffer
(40 mM MOPS pH 7.0, 1 mM EDTA), 10 µl of magne-
sium/ATP cocktail (Final concentrations of 15 mM MgCl2,
100 µM Adenosine tri-phosphate (ATP), 4 mM 3-(N-Mor-
pholino) propanesulfonic acid (MOPS) pH 7.2, 1 mM
Ethylene glycol-bis (2-aminoethylether)-N,N,N',N'-
tetraacetic acid (EGTA), 200 µM sodium orthovanadate
(NaVO3) and 200 µm dithiothreitol (DTT)). The kinase
assay was incubated for 20 minutes at 37°C. GSK-3β
activity was subsequently analyzed by SELDI-TOF-MS.
Traditional kinase assays were performed using 125 ng of
peptide, 2 µl ATP cocktail (1.25 nmoles cold ATP, 1.875 ×
106 cpm [γ-P32] ATP (MP Biomedicals, Irvine CA), 5 µl of
5 × reaction buffer, and 10 µl of magnesium/ATP cocktail,
as described above. 6.25 ng of recombinant GSK-3β was
used in the radio-labeled reaction mixture to a final vol-
ume of 25 µl in HPLC grade water (Sigma-Aldrich, Mil-
waukee, WI). The [γ-P32] labeled peptide was blotted on
p81 phosphocellulose paper (Whatman) and washed 5×
with 100 mM phosphoric acid (Sigma-Aldrich, Milwau-
kee, WI). Incorporation of γ-P32 was quantified in counts
per minute (cpm) by liquid scintillation (Fischer Scien-
tific, Fair Lawn, NJ).
SELDI-TOF mass spectrometry
Kinase assay samples were acidified for ProteinChip®
processing with 10% trifluoroacetic acid (TFA). Equili-
brated Millipore Ziptip® C18 columns (Millipore Corpo-
ration Bedford, MA) were used to bind, wash, and elute
GSK-3β activity in immunoprecipitated NIH 3T3 cell lysates  determined by SELDI Figure 5
GSK-3β activity in immunoprecipitated NIH 3T3 cell 
lysates determined by SELDI. GSK-3β activity was 
determined as described in the text from immunoprecipi-
tated NIH 3T3 cell lysates. SELDI-TOF-MS representative 
spectra displaying the mass/charge ratio (m/z) and signal 
intensities for the 2B-Sp, 2B-S and 2B-A peptides are shown. 
The mass change from 2063.2 Da. to 2143.3 Da. in the 2B-Sp 
chip is consistent with the addition of one phosphate group 
(80 Da.). This experiment was replicated three times and the 
area under the 3143.3 Da. peak was quantitated relative to 
the area under the 2063.2 Da. peak indicating 23.0% +/- 3.5% 
phosphorylation of the 2B-Sp peptide.BMC Biochemistry 2005, 6:29 http://www.biomedcentral.com/1471-2091/6/29
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the kinase assay sample as described by the manufacturer.
Elution samples were spotted on gold (Au) ProteinChip®
Arrays (Ciphergen Biosystems Inc. Fremont Ca.), dried,
and covered with a saturated solution of α-cyano-4-
hydroxy cinnamic acid (CHCA, Sigma, St. Louis, MO)
energy absorbing molecule. Samples were read using the
PBS-II ProteinChip® Reader and the resulting data were
analyzed using the ProteinChip®  Software v3.2 for
changes in mass to charge (m/z) ratios.
Authors' contributions
EB and EM carried out kinase assays, cell culture and
SELDI analysis, as well as interpretation of the data and
first drafting of the manuscript. JCH, BSG and DBO par-
ticipated in study conception and design. BJP carried out
supplemental SELDI analysis and provided technical
advice and trouble-shooting expertise. DBO designed the
cell culture experiments. DBO and BSG coordinated the
entire project, performed final interpretation of the data
and completed the manuscript. All authors read and
approved the final manuscript.
Acknowledgements
The authors would like to thank Dr. Yves Bureau for statistical advice and 
analysis. BSG is the recipient of a Canadian Institutes of Health Research 
Short-Term Clinician Investigator Grant supporting release time for this 
study. BSG also holds a Clinician Scientist Salary Award from the Dept. of 
Surgery at the University of Western Ontario and a Salary Award from the 
Dean's Fund at the Schulich School of Medicine and Dentistry at the Uni-
versity of Western Ontario. Financial support for this work was provided 
by the Canadian Institutes of Health Research and the Lawson Health 
Research Institute Internal Research Fund.
References
1. Ahn NG, Resing KA: Toward the phosphoproteome.  Nat Bio-
technol 2001, 19(4):317-318.
2. Hunter T: Protein kinases and phosphatases: the yin and yang
of protein phosphorylation and signaling.  Cell 1995,
80(2):225-236.
3. Ermak G, Davies KJ: Calcium and oxidative stress: from cell sig-
naling to cell death.  Mol Immunol 2002, 38(10):713-721.
4. Embi N, Rylatt DB, Cohen P: Glycogen synthase kinase-3 from
rabbit skeletal muscle. Separation from cyclic-AMP-depend-
ent protein kinase and phosphorylase kinase.  Eur J Biochem
1980, 107(2):519-527.
5. Hanger DP, Hughes K, Woodgett JR, Brion JP, Anderton BH: Glyco-
gen synthase kinase-3 induces Alzheimer's disease-like phos-
phorylation of tau: generation of paired helical filament
epitopes and neuronal localisation of the kinase.  Neurosci Lett
1992, 147(1):58-62.
6. Diehl JA, Cheng M, Roussel MF, Sherr CJ: Glycogen synthase
kinase-3beta regulates cyclin D1 proteolysis and subcellular
localization.  Genes Dev 1998, 12(22):3499-3511.
7. Watcharasit P, Bijur GN, Song L, Zhu J, Chen X, Jope RS: Glycogen
synthase kinase-3beta (GSK3beta) binds to and promotes
the actions of p53.  J Biol Chem 2003, 278(49):48872-48879.
8. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR: Multiple
Ras-dependent phosphorylation pathways regulate Myc pro-
tein stability.  Genes Dev 2000, 14(19):2501-2514.
9. Kim L, Kimmel AR: GSK3, a master switch regulating cell-fate
specification and tumorigenesis.  Curr Opin Genet Dev 2000,
10(5):508-514.
10. Welsh GI, Proud CG: Glycogen synthase kinase-3 is rapidly
inactivated in response to insulin and phosphorylates
eukaryotic initiation factor eIF-2B.  Biochem J 1993, 294 ( Pt
3):625-629.
11. Jope RS, Johnson GV: The glamour and gloom of glycogen syn-
thase kinase-3.  Trends Biochem Sci 2004, 29(2):95-102.
12. Phiel CJ, Klein PS: Molecular targets of lithium action.  Annu Rev
Pharmacol Toxicol 2001, 41:789-813.
13. Jope RS: Anti-bipolar therapy: mechanism of action of lith-
ium.  Mol Psychiatry 1999, 4(2):117-128.
14. Su Y, Ryder J, Li B, Wu X, Fox N, Solenberg P, Brune K, Paul S, Zhou
Y, Liu F, Ni B: Lithium, a common drug for bipolar disorder
treatment, regulates amyloid-beta precursor protein
processing.  Biochemistry 2004, 43(22):6899-6908.
15. Kozlovsky N, Belmaker RH, Agam G: GSK-3 and the neurodevel-
opmental hypothesis of schizophrenia.  Eur Neuropsychopharma-
col 2002, 12(1):13-25.
16. Murphy E: Inhibit GSK-3beta or there's heartbreak dead
ahead.  J Clin Invest 2004, 113(11):1526-1528.
17. Tong H, Imahashi K, Steenbergen C, Murphy E: Phosphorylation of
glycogen synthase kinase-3beta during preconditioning
through a phosphatidylinositol-3-kinase--dependent path-
way is cardioprotective.  Circ Res 2002, 90(4):377-379.
18. Kaytor MD, Orr HT: The GSK3 beta signaling cascade and neu-
rodegenerative disease.  Curr Opin Neurobiol 2002, 12(3):275-278.
19. Grimes CA, Jope RS: The multifaceted roles of glycogen syn-
thase kinase 3beta in cellular signaling.  Prog Neurobiol 2001,
65(4):391-426.
20. Nikoulina SE, Ciaraldi TP, Mudaliar S, Mohideen P, Carter L, Henry
RR: Potential role of glycogen synthase kinase-3 in skeletal
muscle insulin resistance of type 2 diabetes.  Diabetes 2000,
49(2):263-271.
21. Brabek J, Hanks SK: Assaying protein kinase activity.  Methods
Mol Biol 2004, 284:79-90.
22. Welsh GI, Patel JC, Proud CG: Peptide substrates suitable for
assaying glycogen synthase kinase-3 in crude cell extracts.
Anal Biochem 1997, 244(1):16-21.
23. Ryves WJ, Fryer L, Dale T, Harwood AJ: An assay for glycogen
synthase kinase 3 (GSK-3) for use in crude cell extracts.  Anal
Biochem 1998, 264(1):124-127.
24. Doble BW, Woodgett JR: GSK-3: tricks of the trade for a multi-
tasking kinase.  J Cell Sci 2003, 116(Pt 7):1175-1186.
25. Cadieux PA, Beiko DT, Watterson JD, Burton JP, Howard JC, Knud-
sen BE, Gan BS, McCormick JK, Chambers AF, Denstedt JD, Reid G:
Surface-enhanced laser desorption/ionization-time of flight-
mass spectrometry (SELDI-TOF-MS): a new proteomic uri-
nary test for patients with urolithiasis.  J Clin Lab Anal 2004,
18(3):170-175.
26. Aebersold R, Mann M: Mass spectrometry-based proteomics.
Nature 2003, 422(6928):198-207.
27. Thulasiraman V, Wang Z, Katrekar A, Lomas L, Yip TT: Simultane-
ous monitoring of multiple kinase activities by SELDI-TOF
mass spectrometry.  Methods Mol Biol 2004, 264:205-214.
28. Tolson J, Bogumil R, Brunst E, Beck H, Elsner R, Humeny A, Kratzin
H, Deeg M, Kuczyk M, Mueller GA, Mueller CA, Flad T: Serum pro-
tein profiling by SELDI mass spectrometry: detection of
multiple variants of serum amyloid alpha in renal cancer
patients.  Lab Invest 2004, 84(7):845-856.
29. Rosty C, Christa L, Kuzdzal S, Baldwin WM, Zahurak ML, Carnot F,
Chan DW, Canto M, Lillemoe KD, Cameron JL, Yeo CJ, Hruban RH,
Goggins M: Identification of hepatocarcinoma-intestine-pan-
creas/pancreatitis-associated protein I as a biomarker for
pancreatic ductal adenocarcinoma by protein biochip tech-
nology.  Cancer Res 2002, 62(6):1868-1875.
30. Xiao Z, Adam BL, Cazares LH, Clements MA, Davis JW, Schellham-
mer PF, Dalmasso EA, Wright GLJ: Quantitation of serum pros-
tate-specific membrane antigen by a novel protein biochip
immunoassay discriminates benign from malignant prostate
disease.  Cancer Res 2001, 61(16):6029-6033.
31. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW: Proteomics and
bioinformatics approaches for identification of serum
biomarkers to detect breast cancer.  Clin Chem 2002,
48(8):1296-1304.
32. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg
SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA: Use of
proteomic patterns in serum to identify ovarian cancer.  Lan-
cet 2002, 359(9306):572-577.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Biochemistry 2005, 6:29 http://www.biomedcentral.com/1471-2091/6/29
Page 9 of 9
(page number not for citation purposes)
3 3 . R e i n d e r s  J ,  L e w a n d r o w s k i  U ,  M o e b i u s  J ,  W a g n e r  Y ,  S i c k m a n n  A :
Challenges in mass spectrometry-based proteomics.  Pro-
teomics 2004, 4(12):3686-3703.
34. Salih E: Phosphoproteomics by mass spectrometry and classi-
cal protein chemistry approaches.  Mass Spectrom Rev 2004.
35. Wang QM, Roach PJ, Fiol CJ: Use of a synthetic peptide as a
selective substrate for glycogen synthase kinase 3.  Anal Bio-
chem 1994, 220(2):397-402.
36. Cohen P, Frame S: The renaissance of GSK3.  Nat Rev Mol Cell Biol
2001, 2(10):769-776.
37. Mandelkow EM, Drewes G, Biernat J, Gustke N, Van Lint J, Vanden-
heede JR, Mandelkow E: Glycogen synthase kinase-3 and the
Alzheimer-like state of microtubule-associated protein tau.
FEBS Lett 1992, 314(3):315-321.
38. Kaidanovich O, Eldar-Finkelman H: The role of glycogen synthase
kinase-3 in insulin resistance and Type 2 diabetes.  Expert Opin
Ther Targets 2002, 6(5):555-561.